DekaBank Deutsche Girozentrale Sells 69,500 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

DekaBank Deutsche Girozentrale decreased its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 14.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 411,897 shares of the company's stock after selling 69,500 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.17% of BioNTech worth $36,620,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in shares of BioNTech by 18,892.9% during the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock valued at $63,593,000 after purchasing an additional 694,691 shares during the period. GF Fund Management CO. LTD. grew its stake in shares of BioNTech by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after purchasing an additional 453 shares during the last quarter. OneDigital Investment Advisors LLC bought a new stake in shares of BioNTech in the 1st quarter worth approximately $288,000. Vontobel Holding Ltd. lifted its stake in BioNTech by 2.3% during the first quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company's stock valued at $1,993,000 after purchasing an additional 497 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new stake in BioNTech during the first quarter worth approximately $105,000. 15.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Morgan Stanley set a $133.00 price objective on BioNTech and gave the company an "overweight" rating in a research report on Thursday. Truist Financial reiterated a "buy" rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Leerink Partners set a $112.00 target price on shares of BioNTech in a report on Monday, June 2nd. Citigroup restated a "buy" rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Finally, Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $137.91.

BioNTech Stock Performance

Shares of BNTX traded down $1.03 during trading hours on Friday, reaching $112.89. 521,908 shares of the company traded hands, compared to its average volume of 943,543. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The stock's fifty day moving average is $103.56 and its 200 day moving average is $106.81. BioNTech SE Sponsored ADR has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a market cap of $27.14 billion, a P/E ratio of -33.20 and a beta of 1.29.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.